+---------------------------------+---+-------+--------+-----------------+
| # BIOGRAPHICAL SKETCH           |   |       |        |                 |
|                                 |   |       |        |                 |
| Provide the following           |   |       |        |                 |
| information for the key         |   |       |        |                 |
| personnel and other significant |   |       |        |                 |
| contributors in the order       |   |       |        |                 |
| listed on Form Page 2\          |   |       |        |                 |
| Follow this format for each     |   |       |        |                 |
| person. **DO NOT EXCEED FOUR    |   |       |        |                 |
| PAGES**                         |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| NAME                            |   | POS   |        |                 |
|                                 |   | ITION |        |                 |
| **Joe W. Gray, PhD**            |   | TITLE |        |                 |
|                                 |   |       |        |                 |
|                                 |   | Div   |        |                 |
|                                 |   | ision |        |                 |
|                                 |   | Dir   |        |                 |
|                                 |   | ector |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| eRA COMMONS USER NAME           |   |       |        |                 |
|                                 |   |       |        |                 |
| Joegray                         |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| EDUCATION/TRAINING *(Begin with |   |       |        |                 |
| baccalaureate or other initial  |   |       |        |                 |
| professional education, such as |   |       |        |                 |
| nursing, and include            |   |       |        |                 |
| postdoctoral training.)*        |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| INSTITUTION AND LOCATION        | D |       | Y      | FIELD OF STUDY  |
|                                 | E |       | EAR(s) |                 |
|                                 | G |       |        |                 |
|                                 | R |       |        |                 |
|                                 | E |       |        |                 |
|                                 | E |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| Colorado School of Mines,       | P |       | 1968   | Physics         |
| Golden, CO                      | r |       |        |                 |
|                                 | o |       |        |                 |
|                                 | f |       |        |                 |
|                                 | . |       |        |                 |
|                                 | E |       |        |                 |
|                                 | n |       |        |                 |
|                                 | g |       |        |                 |
|                                 | . |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| Kansas State University,        | P |       | 1972   | Physics         |
| Manhattan, KS                   | h |       |        |                 |
|                                 | . |       |        |                 |
|                                 | D |       |        |                 |
|                                 | . |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+

Positions and Honors

1972 -- 1991 Biomedical Scientist, Biomedical Sciences Division,
Lawrence Livermore National Laboratory (LLNL), Livermore, CA

1982 -- 1991 Cytophysics Section Leader, Biomedical Sciences Division,
LLNL, Livermore, CA

1984 -- 1991 Adjunct Professor of Laboratory Medicine, UCSF, San
Francisco, CA

1990 -- 1995 Member, National Advisory Council for Human Genome
Research.

1991 -- 2003 Professor of Laboratory Medicine and Radiation Oncology,
UCSF, San Francisco, CA

2003 -- present Adj. Professor of Laboratory Medicine and Radiation
Oncology, UCSF, San Francisco, CA

1991 -- 1997 Director; Division of Molecular Cytometry, Dept. of Lab.
Med. UCSF, San Francisco. CA

1992 -- 1998 Senior Scientist (faculty), Lawrence Berkeley National
Laboratory (LBNL), Berkeley, CA

1992 -- 1998 Director, Resource for Molecular Cytogenetics, LBNL,
Berkeley, CA

1995 -- 1997 Interim Director, UCSF Cancer Center, UCSF, San Francisco,
CA

1997 -- 2002 Science Council; Radiation Effects Research Foundation

1997 -- present Program Leader; Breast Oncology, UCSF Comprehensive
Cancer Center, San Francisco, CA

1999 -- 2003 Member, Genome Study Section

2003 -- present Director, Division of Life Sciences, Lawrence Berkeley
National Laboratory, Berkeley, CA

2003 -- present Associate Laboratory Director for Life and Env. Sci.,
Lawrence Berkeley National Laboratory, Berkeley, CA

2004 -- present Member, Board of Scientific Advisors, National Cancer
Institute, NIH

2005 -- 2007 Translational Research Working Group, National Cancer
Institute, NIH

2006 -- 2007 Member, Committee on the state of science in nuclear
medicine, Nat'l Academy Science.

Awards

Research Award, 13th Radiation Research Society, 1985; E.O. Lawrence
Award, U.S. Department of Energy, 1986; Fellow, American Association for
the Advancement of Science, 1996; Exceptional Service Award, U.S.
Department of Energy, 1997; Schiffer Award, Cell Proliferation Society,
1999; Boerhaave Professor, Leiden University, the Netherlands, 2000;
Curt Stern Award, American Society for Human Genetics, 2001; SPORE
Leadership Award, National SPORE office, 2003; Alumni Fellow, Kansas
State University, 2005; Distinguished Achievement Award, Colorado School
of Mines, 2005; Doctor of Medicine, *Honoris Causa*, Tampere University,
2005; DOD Innovator Award, 2007; Brinker Award for Scientific
Distinction: Basic Science, 2007; AACR Team Science Award, 2008.

Publications (Selected from 335 total)

Chin, L and Gray, JW. (2008) Translating insights from the cancer genome
into clinical practice. Nature. 452:553-63.

TCGA Research Network (2008) Comprehensive genomic characterization
defines human glioblastoma genes and core pathways. Nature. 2008 Sep 4.
\[Epub ahead of print\]

Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET;
Translational Research Working Group. (2008) Translational Research
Working Group developmental pathway for biospecimen-based assessment
modalities. Clin Cancer Res.14:5672-7.

Guan Y, Kuo W-L, Stilwell J, Takano H, Lapuk A, Fridlyand J, Mao J-H, Yu
M, Miller M, Santos J, Kalloger S, Carlson J,  Ginzinger D, Celniker S,
Mills GB Huntsman D., and Gray JW. Amplification of PVT1 contributes to
the pathophysiology of ovarian and breast cancer. Clinical Cancer Res.
13:5745-5755, 2007.

Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K,
Lee EH, Barcellos-Hoff MH, Petersen OW, Gray^,^ JW, and Bissell MJ.
(2007) The morphologies of breast cancer cell lines in three-dimensional
assays correlate with their profiles of gene expression. Molecular
Oncology, 1(1): 84-96.

## Mao JH, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, Gray JW, Cai WW, and Balmain A. (2007) Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell, 11:161-73.

Chin K, DeVries S, Fridlyand J, Spellman^,^ P, Roydasgupta R, Kuo W-L,
Lapuk A, Neve R, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley
C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung B, Esserman L,
Albertson D, Waldman F, and Gray JW. (2006) Genomic and transcriptional
aberrations linked to breast cancer pathophysiologies. Cancer Cell,
10:529-41.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner F, Fevr T, Clark L, Bayani
N, Coppe J, Tong F, Speed T, Spellman PT, Devries S, Lapuk A, Wang NJ,
Kuo W-L, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F,
Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, and Gray JW.
(2006) A collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell, 10:515-27.

Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW,
and McCormick F. (2005) A conditional feedback loop regulates Ras
activity through EphA2. Cancer Cell, 8:111-8.

Hodgson JG, Malek T, Bornstein S, Hariono S, Ginzinger DG, Muller WJ,
and Gray JW. (2005) Copy number aberrations in mouse breast tumors
reveal loci and genes important in tumorigenic receptor tyrosine kinase
signaling. Cancer Res., 65:9695-704.**Patents (Selected from 59 total)**

Dolbeare F and Gray JW. Flow cytometric measurement of total DNA and
incorporated halodeoxyuridine. U.S. Patents #4,585,736 (1986);
#4,780,406 (1988); #4,812,394 (1989).

Gray JW and Pinkel D. Methods for chromosome-specific staining. U.S.
Patents #5,447,841 (1995); #6,596,479 (2003); #6,607,877 (2003);
#6,872,817 (2005).

Pinkel D, Gray JW, Kallioniemi A, Kallioniemi O-P, Sakamoto M, and
Waldman F. Comparative genomic hybridization (CGH). U.S. Patents
#5,665,549 (1997); #5,721,098 (1998); #5,965,362 (1999); #5,976,790
(1999); #6,159,685 (2000); #6,335,167 (2002); #7,238,484 (2007).

Shayesteh L and Gray JW. Genetic alterations associated with cancer.
U.S. Patents #6,277,563 (2001); #6,475,732 B1 (2002).

Collins C, Volik S, and Gray JW. End sequence profiling. U.S. Patent
#6,785,614 (2004).

**Research Support**

**[Ongoing Research Support]{.underline}**

P50 CA58207 (Gray) 09/30/92 -- 11/30/12

NIH/NCI

Bay Area Breast Cancer Translational Research Program (SPORE)

Project 2: Molecular Determinants of Response to Therapy and New
Strategies to Treat Resistant Tumors (Gray)

The goal of this project is to test the hypothesis that aberrations
involving receptor tyrosine kinase signaling downstream of activated
growth factor receptors will modulate responses to receptor inhibitors.
Development of predictors of responses of ERBB2 positive tumors to
Herceptin will be approached first. This will be attempted by in vitro
analyses of a collection of 60 breast cancer cell lines.

Role: Project PI

Administrative Core (Gray)

This Core is the operational backbone of the SPORE and provides overall
administrative and financial management for all projects/cores.

Role: Core Director

P30 CA82103 (McCormick) 08/05/99 -- 05/31/12

NIH/NCI

Cancer Center Support Grant

This grant provides support for Cancer Center infrastructure and program
leadership. Dr. Gray is the Program Leader of the Breast Oncology
Program.

P50 CA83639 (Bast) 09/01/99 -- 08/31/11

NIH/NCI

SPORE in Ovarian Cancer/Markers for Assessment of Response to Therapy

This project supports genomic analysis of ovarian cancers with the goal
of identifying aberrations that predict clinical outcome.

Role: Project PI

U54 CA112970 (Gray) 09/30/04 -- 08/31/09

NIH/NCI

Systems--Based Predications of Responses to Cancer Therapy

The goal of this program is to develop and experimentally validate a
computational model of Raf--MEK--ERK signaling in breast cancer that
will predict individual responses to therapeutic agents that inhibit
Raf--MEK--ERK signaling.

Role: PI

SmithKline Beecham Corporation (Gray) 01/01/06 -- 1/26/09

Molecular Predictors of Drug Response in Breast Cancer

The goal of this project is to provide GSK with a set of gene expression
and protein level markers that predict the response (apoptosis, change
in proliferation index and/or change in growth rate) to two GSK
compounds in a panel of 50 breast cancer cell lines and test these in
breast cancer cell lines grown in matrigel cultures and as xenografts.
Also, to optimize cell culture instrumentation and software to
facilitate current and future compound evaluation.

Role: PI

U24 CA126477 (Fisher) 09/28/06 -- 08/31/11

NIH/NCI

Targeted and Global Proteomic Strategies for Early Breast Cancer
Detection

The goal of this multi-institutional project is to develop a targeted
strategy for discovery of molecular markers in serum that signal the
presence of early breast cancer.

Role: Co-PI

U24 CA126477 (Gray) 09/28/06 -- 08/31/09

NIH/NCI/NHGRI

The Berkeley Cancer Genome Center

The goal of this multi-institutional project is to assess
transcriptional changes in human brain, lung and ovarian cancers
provided by the NCI and NHGRI as part of the Cancer Genome Anatomy
Project.

Role: PI

BC061995 (Gray) 09/17/07 -- 09/16/12

USAMRMC

Early Detection of Metastasis-Prone Breast Cancers

The goal of this multi-institutional project is to develop anatomic and
histologic molecular imaging strategies to detect metastasis prone
breast cancers before they have metastasized.

Role: PI

**[Completed Research Support]{.underline}**

Cellgate (Gray) 11/01/06 -- 10/31/07

Molecular Predictors of Biological Response in Breast Cancer

The goal of this project is to provide Cellgate with a set of gene
expression and protein level markers that predict the response
(apoptosis, change in proliferation index and/or change in growth rate)
to GSK compounds in a panel of 50 breast cancer cell lines.

Role: PI

NNA06CA81A (Gray) 10/01/05 -- 09/30/07

NASA Ames

Nanoelectrode Proteomics Array for Kinase Activity Profiling toward
Early Cancer Diagnosis during Space Travel.

The goal of this project is to develop an ultrasensitive, multiplex, and
label-free proteomics chip for astronaut healthcare through quick kinase
activity profiling and correlate the kinase profiles to cancer
diagnosis.

Role: PI

U54 CA090788 (Tempero) 09/26/01 -- 12/31/07

NIH/NCI

Mechanism Based Evaluations of ErbB Targeted Agents

Project: Interactions of the ErB--Receptor Tyrosine Kinases in Breast
Cancer

The overall goal of this project is to develop molecular markers that
predict response to EGFR--family inhibitors, especially Herceptin and
Omnitarg.

Role: Project PI

UO1 ES012801 (Hiatt) 09/29/03 -- 09/28/10

NIEHS

Bay Area Breast Cancer and the Environment Research Center/Environmental
Effects on the Molecular Architecture and Function of the Mammary Gland
across the Lifespan (Werb, Project 1)

This project studies environmental effects on the molecular architecture
and function of the mammary gland across the lifespan.

Role: Co-investigator - terminated

NNA04CF751 (Barcellos--Hoff) 10/01/03 -- 09/30/08

NSCOR, NASA

Mechanisms of HZE Damage and Repair in Human Epithelial Cells

The goal of this project is to determine using state--of--the--art
imaging, genomic and genetic tools which dose and radiation quality,
under what cellular and microenvironment circumstances, affect normal
epithelial cell behavior associated with cancer risk.

Role: Co-investigator